Stockreport

Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer

Exelixis, Inc.  (EXEL) 
Last exelixis, inc. earnings: 2/25 04:05 pm Check Earnings Report
PDF – The FDA assigned a Prescription Drug User Fee Act target action date of December 3, 2026 –– Application is based on results from the phase 3 STELLAR-303 pivotal trial, [Read more]